Evidence map›Paper›PMID 36678738›Full record

ReviewPharmaceutics2022

Multifunctional Photoactive Nanomaterials for Photodynamic Therapy against Tumor: Recent Advancements and Perspectives.

Rupesh Jain, Shambo Mohanty, Ila Sarode, Swati Biswas, Gautam Singhvi, Sunil Kumar Dubey

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. The Latest Look at PDT and Immune Checkpoints.Current issues in molecular biology · 2024
    Review
  6. Advances in Nanodynamic Therapy for Cancer Treatment.Nanomaterials (Basel, Switzerland) · 2024
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Rupesh JainDepartment of Pharmacy, Birla Institute of Technology and Science-Pilani, Pilani Campus, Pilani 333031, Rajasthan, India.ORCID 0000-0001-9625-8396
Shambo MohantyDepartment of Pharmacy, Birla Institute of Technology and Science-Pilani, Pilani Campus, Pilani 333031, Rajasthan, India.
Ila SarodeDepartment of Pharmacy, Birla Institute of Technology and Science-Pilani, Pilani Campus, Pilani 333031, Rajasthan, India.
Swati BiswasDepartment of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad Campus, Hyderabad 500078, Telangana, India.ORCID 0000-0002-1575-4206
Gautam SinghviDepartment of Pharmacy, Birla Institute of Technology and Science-Pilani, Pilani Campus, Pilani 333031, Rajasthan, India.ORCID 0000-0002-9706-9244
Sunil Kumar DubeyDepartment of Pharmacy, Birla Institute of Technology and Science-Pilani, Pilani Campus, Pilani 333031, Rajasthan, India.
Birla Institute of Technology and Science, Pilani · INBirla Institute of Technology and Science - Hyderabad Campus · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous treatments are available for cancer, including chemotherapy, immunotherapy, radiation therapy, hormone therapy, biomarker testing, surgery, photodynamic therapy, etc. Photodynamic therapy (PDT) is an effective, non-invasive, novel, and clinically approved strategy to treat cancer. In PDT, three main agents are utilized, i.e., photosensitizer (PS) drug, oxygen, and light. At first, the photosensitizer is injected into blood circulation or applied topically, where it quickly becomes absorbed or accumulated at the tumor site passively or actively. Afterward, the tumor is irradiated with light which leads to the activation of the photosensitizing molecule. PS produces the reactive oxygen species (ROS), resulting in the death of the tumor cell. However, the effectiveness of PDT for tumor destruction is mainly dependent on the cellular uptake and water solubility of photosensitizer molecules. Therefore, the delivery of photosensitizer molecules to the tumor cell is essential in PDT against cancer. The non-specific distribution of photosensitizer results in unwanted side effects and unsuccessful therapeutic outcomes. Therefore, to improve PDT clinical outcomes, the current research is mostly focused on developing actively targeted photosensitizer molecules, which provide a high cellular uptake and high absorption capacity to the tumor site by overcoming the problem associated with conventional PDT. Therefore, this review aims to provide current knowledge on various types of actively and passively targeted organic and inorganic nanocarriers for different cancers.

Indexed as

actively targeted drug deliverycancernanocarriersphotodynamic therapy

Identifiers

PMID36678738
PMCPMC9866498
OpenAlexW4313327197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.